公开(公告)号：US20170240614A1

公开(公告)日：2017-08-24

申请号：US15434477

申请日：2017-02-16

Applicant: Eli Lilly and Company ,  Amunix Operating Inc.

Inventor： David Bruce BALDWIN ,  John Michael BEALS ,  Andrew Ihor KORYTKO ,  Bryant Rhodius McLAUGHLIN ,  Volker SCHELLENBERGER

IPC: C07K14/72 ,  A61K38/17 ,  C07K14/71

CPC classification number: C07K14/72 ,  A61K38/179 ,  A61K38/1796 ,  A61K38/28 ,  A61K47/64 ,  C07K14/62 ,  C07K14/71 ,  C07K2319/31

Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound.

公开(公告)号：US20220175891A1

公开(公告)日：2022-06-09

申请号：US17551904

申请日：2021-12-15

Applicant: Eli Lilly and Company

Inventor： John Michael BEALS ,  Eric Dwayne HAWKINS ,  Anthony Shane RANSDELL ,  Shantanu Virendra SULE ,  Monica Rixman SWINNEY

IPC: A61K38/28 ,  A61P3/10 ,  A61K31/167 ,  A61K31/196 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/625 ,  A61K31/727 ,  A61K33/30 ,  A61K47/10

Abstract: The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.

公开(公告)号：US20250032588A1

公开(公告)日：2025-01-30

申请号：US18756062

申请日：2024-06-27

Applicant: ELI LILLY AND COMPANY

Inventor： David Bruce BALDWIN ,  John Michael BEALS ,  Jonathan Wesley DAY ,  Craig Duane DICKINSON ,  Andrew Ihor KORYTKO ,  Gregory Alan LAZAR

IPC: A61K38/28 ,  A61K38/00 ,  A61K38/16 ,  A61K38/26 ,  C07K14/00 ,  C07K14/62

Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.

公开(公告)号：US20250000950A1

公开(公告)日：2025-01-02

申请号：US18709721

申请日：2022-11-14

Applicant: ELI LILLY AND COMPANY

Inventor： David Paul ALLEN ,  John Michael BEALS ,  Vincent John CORVARI ,  Patrick Daniel DONOVAN ,  Ken Kangyi QIAN ,  Wei WANG

IPC: A61K38/28 ,  A61K47/02 ,  A61K47/10

Abstract: Described herein are preserved formulations of insulin-Fc fusions. The formulations include insulin-Fc fusions having prolonged pharmacokinetic and pharmacodynamic profiles sufficient for once weekly administration in the treatment of diabetes and are sufficiently stable to allow for storage and use without unacceptable loss of chemical or physical stability.

公开(公告)号：US20200261545A1

公开(公告)日：2020-08-20

申请号：US16645199

申请日：2018-08-03

Applicant: Eli Lilly and Company

Inventor： John Michael BEALS ,  Eric Dwayne HAWKINS ,  Anthony Shane RANSDELL ,  Shantanu Virendra SULE ,  Monica Rixman SWINNEY

IPC: A61K38/28 ,  A61K31/5415 ,  A61K31/625 ,  A61K31/573 ,  A61K31/727 ,  A61K31/167 ,  A61K31/196 ,  A61K47/10 ,  A61K33/30 ,  A61P3/10

Abstract: The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.